Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 4/2015

01-04-2015 | Article

Trends and correlation of antibacterial usage and bacterial resistance: time series analysis for antibacterial stewardship in a Chinese teaching hospital (2009–2013)

Authors: Y. M. Zou, Y. Ma, J. H. Liu, J. Shi, T. Fan, Y. Y. Shan, H. P. Yao, Y. L. Dong

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 4/2015

Login to get access

Abstract

The purpose of this investigation was to describe the effect of antibacterial stewardship and evaluate the trends and correlation of antibacterial resistance and usage from 2009 to 2013 in a tertiary-care teaching hospital in northwest China. Antibacterial usage was expressed as defined daily doses per 100 patients per day (DDDs/100 PDs). Hospital-wide population-level data and time series analysis were used to evaluate the trends and determine associations between antibacterial exposure and acquisition of resistance. Yearly consumption of overall antibacterials significantly decreased from 66.54 to 28.08 DDDs/100 PDs (β = −10.504, p < 0.01). The resistant rates of the five most frequently isolated species (including Escherichia coli, Acinetobacter baumannii, Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae) significantly decreased or remained stable, and none of them showed a statistically significant upward trend. The medical quality indicators got better or remained stable. Autoregressive integrated moving average (ARIMA) models demonstrated that the monthly resistance rate of P. aeruginosa to imipenem was strongly correlated with antipseudomonal carbapenems usage (β = 34.94, p < 0.001), as did the correlation of P. aeruginosa to meropenem with antipseudomonal third-generation cephalosporins usage (β = 32.76, p < 0.01) and K. pneumoniae to amikacin with aminoglycosides usage (β = 22.01, p < 0.001). The decreased antibacterial use paralleled the improved bacterial resistance without deteriorating medical quality indicators during antimicrobial stewardship. It also suggests that optimum antibiotic use is necessary to alleviate the threat posed by resistant microorganisms at the hospital level.
Literature
1.
go back to reference Wise R, Hart T, Cars O, Streulens M, Helmuth R, Huovinen P, Sprenger M (1998) Antimicrobial resistance. Is a major threat to public health. BMJ 317:609–610CrossRefPubMedCentralPubMed Wise R, Hart T, Cars O, Streulens M, Helmuth R, Huovinen P, Sprenger M (1998) Antimicrobial resistance. Is a major threat to public health. BMJ 317:609–610CrossRefPubMedCentralPubMed
2.
go back to reference Levy SB, Marshall B (2004) Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10:S122–129CrossRefPubMed Levy SB, Marshall B (2004) Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10:S122–129CrossRefPubMed
3.
go back to reference Roberts RR, Hota B, Ahmad I, Scott RD 2nd, Foster SD, Abbasi F, Schabowski S, Kampe LM, Ciavarella GG, Supino M, Naples J, Cordell R, Levy SB, Weinstein RA (2009) Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: Implications for antibiotic stewardship. Clin Infect Dis 49:1175–1184CrossRefPubMed Roberts RR, Hota B, Ahmad I, Scott RD 2nd, Foster SD, Abbasi F, Schabowski S, Kampe LM, Ciavarella GG, Supino M, Naples J, Cordell R, Levy SB, Weinstein RA (2009) Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: Implications for antibiotic stewardship. Clin Infect Dis 49:1175–1184CrossRefPubMed
4.
go back to reference Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, Mobashery S, Piddock LJ, Projan S, Thomas CM, Tomasz A, Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P, Zgurskaya HI (2011) Tackling antibiotic resistance. Nat Rev Microbiol 12:894–896CrossRef Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, Mobashery S, Piddock LJ, Projan S, Thomas CM, Tomasz A, Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P, Zgurskaya HI (2011) Tackling antibiotic resistance. Nat Rev Microbiol 12:894–896CrossRef
5.
go back to reference Sousa D, Castelo-Corral L, Gutiérrez-Urbón JM, Molina F, López-Calviño B, Bou G, Llinares P (2013) Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: collateral damage or positive effect on hospital ecology? J Antimicrob Chemother 68:1917–1925CrossRefPubMed Sousa D, Castelo-Corral L, Gutiérrez-Urbón JM, Molina F, López-Calviño B, Bou G, Llinares P (2013) Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: collateral damage or positive effect on hospital ecology? J Antimicrob Chemother 68:1917–1925CrossRefPubMed
6.
go back to reference Pires dos Santos R, Jacoby T, Pires Machado D, Lisboa T, Gastal SL, Nagel FM, Kuplich NM, Konkewicz L, Gorniak Lovatto C, Pires MR, Goldani LZ (2011) Hand hygiene, and not ertapenem use, contributed to reduction of carbapenem-resistant Pseudomonas aeruginosa rates. Infect Control Hosp Epidemiol 32:584–590CrossRefPubMed Pires dos Santos R, Jacoby T, Pires Machado D, Lisboa T, Gastal SL, Nagel FM, Kuplich NM, Konkewicz L, Gorniak Lovatto C, Pires MR, Goldani LZ (2011) Hand hygiene, and not ertapenem use, contributed to reduction of carbapenem-resistant Pseudomonas aeruginosa rates. Infect Control Hosp Epidemiol 32:584–590CrossRefPubMed
7.
go back to reference Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America (2007) Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44:159–177CrossRefPubMed Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America (2007) Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44:159–177CrossRefPubMed
8.
go back to reference Mölstad S, Erntell M, Hanberger H, Melander E, Norman C, Skoog G, Lundborg CS, Söderström A, Torell E, Cars O (2008) Sustained reduction of antibiotic use and low bacterial resistance: 10-year follow-up of the Swedish Strama programme. Lancet Infect Dis 8:125–132CrossRefPubMed Mölstad S, Erntell M, Hanberger H, Melander E, Norman C, Skoog G, Lundborg CS, Söderström A, Torell E, Cars O (2008) Sustained reduction of antibiotic use and low bacterial resistance: 10-year follow-up of the Swedish Strama programme. Lancet Infect Dis 8:125–132CrossRefPubMed
9.
go back to reference Bager F (2000) DANMAP: monitoring antimicrobial resistance in Denmark. Int J Antimicrob Agents 14:271–274CrossRefPubMed Bager F (2000) DANMAP: monitoring antimicrobial resistance in Denmark. Int J Antimicrob Agents 14:271–274CrossRefPubMed
10.
go back to reference Mölstad S, Cars O (1999) Major change in the use of antibiotics following a national programme: Swedish Strategic Programme for the Rational Use of Antimicrobial Agents and Surveillance of Resistance (STRAMA). Scand J Infect Dis 31:191–195CrossRefPubMed Mölstad S, Cars O (1999) Major change in the use of antibiotics following a national programme: Swedish Strategic Programme for the Rational Use of Antimicrobial Agents and Surveillance of Resistance (STRAMA). Scand J Infect Dis 31:191–195CrossRefPubMed
11.
go back to reference Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE Jr, Archibald LK, Gaynes RP, Tenover FC (1999) Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 29:245–52CrossRefPubMed Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE Jr, Archibald LK, Gaynes RP, Tenover FC (1999) Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 29:245–52CrossRefPubMed
12.
go back to reference Martínez JA, Delgado E, Martí S, Marco F, Vila J, Mensa J, Torres A, Codina C, Trilla A, Soriano A, Alquezar A, Castro P, Nicolás JM (2009) Influence of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance in critically ill medical patients. Intensive Care Med 35:439–447CrossRefPubMed Martínez JA, Delgado E, Martí S, Marco F, Vila J, Mensa J, Torres A, Codina C, Trilla A, Soriano A, Alquezar A, Castro P, Nicolás JM (2009) Influence of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance in critically ill medical patients. Intensive Care Med 35:439–447CrossRefPubMed
13.
go back to reference Nouér SA, Nucci M, De-Oliveira MP, Pellegrino FL, Moreira BM (2005) Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. Antimicrob Agents Chemother 49:3663–3667CrossRefPubMedCentralPubMed Nouér SA, Nucci M, De-Oliveira MP, Pellegrino FL, Moreira BM (2005) Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. Antimicrob Agents Chemother 49:3663–3667CrossRefPubMedCentralPubMed
14.
go back to reference Ozkurt Z, Ertek M, Erol S, Altoparlak U, Akcay MN (2005) The risk factors for acquisition of imipenem-resistant Pseudomonas aeruginosa in the burn unit. Burns 31:870–873CrossRefPubMed Ozkurt Z, Ertek M, Erol S, Altoparlak U, Akcay MN (2005) The risk factors for acquisition of imipenem-resistant Pseudomonas aeruginosa in the burn unit. Burns 31:870–873CrossRefPubMed
15.
go back to reference Su CH, Wang JT, Hsiung CA, Chien LJ, Chi CL, Yu HT, Chang FY, Chang SC (2012) Increase of carbapenem-resistant Acinetobacter baumannii infection in acute care hospitals in Taiwan: association with hospital antimicrobial usage. PLoS One 7:e37788CrossRefPubMedCentralPubMed Su CH, Wang JT, Hsiung CA, Chien LJ, Chi CL, Yu HT, Chang FY, Chang SC (2012) Increase of carbapenem-resistant Acinetobacter baumannii infection in acute care hospitals in Taiwan: association with hospital antimicrobial usage. PLoS One 7:e37788CrossRefPubMedCentralPubMed
17.
go back to reference Iosifidis E, Antachopoulos C, Tsivitanidou M, Katragkou A, Farmaki E, Tsiakou M, Kyriazi T, Sofianou D, Roilides E (2008) Differential correlation between rates of antimicrobial drug consumption and prevalence of antimicrobial resistance in a tertiary care hospital in Greece. Infect Control Hosp Epidemiol 29:615–622CrossRefPubMed Iosifidis E, Antachopoulos C, Tsivitanidou M, Katragkou A, Farmaki E, Tsiakou M, Kyriazi T, Sofianou D, Roilides E (2008) Differential correlation between rates of antimicrobial drug consumption and prevalence of antimicrobial resistance in a tertiary care hospital in Greece. Infect Control Hosp Epidemiol 29:615–622CrossRefPubMed
18.
go back to reference Messadi AA, Lamia T, Kamel B, Salima O, Monia M, Saida BR (2008) Association between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in an intensive care burn unit: a 5-year study, 2000–2004. Burns 34:1098–1102CrossRefPubMed Messadi AA, Lamia T, Kamel B, Salima O, Monia M, Saida BR (2008) Association between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in an intensive care burn unit: a 5-year study, 2000–2004. Burns 34:1098–1102CrossRefPubMed
19.
go back to reference Lepper PM, Grusa E, Reichl H, Högel J, Trautmann M (2002) Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 46:2920–2925CrossRefPubMedCentralPubMed Lepper PM, Grusa E, Reichl H, Högel J, Trautmann M (2002) Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 46:2920–2925CrossRefPubMedCentralPubMed
20.
go back to reference Tacconelli E, De Angelis G, Cataldo MA, Mantengoli E, Spanu T, Pan A, Corti G, Radice A, Stolzuoli L, Antinori S, Paradisi F, Carosi G, Bernabei R, Antonelli M, Fadda G, Rossolini GM, Cauda R (2009) Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob Agents Chemother 53:4264–4269CrossRefPubMedCentralPubMed Tacconelli E, De Angelis G, Cataldo MA, Mantengoli E, Spanu T, Pan A, Corti G, Radice A, Stolzuoli L, Antinori S, Paradisi F, Carosi G, Bernabei R, Antonelli M, Fadda G, Rossolini GM, Cauda R (2009) Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob Agents Chemother 53:4264–4269CrossRefPubMedCentralPubMed
21.
go back to reference Tacconelli E, Venkataraman L, De Girolami PC, Dagata EM (2004) Methicillin-resistant Staphylococcus aureus bacteraemia diagnosed at hospital admission: distinguishing between community-acquired versus healthcare-associated strains. J Antimicrob Chemother 53:474–479CrossRefPubMed Tacconelli E, Venkataraman L, De Girolami PC, Dagata EM (2004) Methicillin-resistant Staphylococcus aureus bacteraemia diagnosed at hospital admission: distinguishing between community-acquired versus healthcare-associated strains. J Antimicrob Chemother 53:474–479CrossRefPubMed
22.
go back to reference Livermore DM (2004) Can better prescribing turn the tide of resistance? Nat Rev Microbiol 2:73–78CrossRefPubMed Livermore DM (2004) Can better prescribing turn the tide of resistance? Nat Rev Microbiol 2:73–78CrossRefPubMed
23.
go back to reference Cosby JL, Francis N, Butler CC (2007) The role of evidence in the decline of antibiotic use for common respiratory infections in primary care. Lancet Infect Dis 7:749–756CrossRefPubMed Cosby JL, Francis N, Butler CC (2007) The role of evidence in the decline of antibiotic use for common respiratory infections in primary care. Lancet Infect Dis 7:749–756CrossRefPubMed
24.
go back to reference Strateva T, Yordanov D (2009) Pseudomonas aeruginosa—a phenomenon of bacterial resistance. J Med Microbiol 58:1133–1148CrossRefPubMed Strateva T, Yordanov D (2009) Pseudomonas aeruginosa—a phenomenon of bacterial resistance. J Med Microbiol 58:1133–1148CrossRefPubMed
25.
go back to reference Mesaros N, Nordmann P, Plésiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, Van Bambeke F (2007) Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 13:560–578CrossRefPubMed Mesaros N, Nordmann P, Plésiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, Van Bambeke F (2007) Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 13:560–578CrossRefPubMed
26.
go back to reference Rice LB (2006) Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 43:S100–S105CrossRefPubMed Rice LB (2006) Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 43:S100–S105CrossRefPubMed
27.
go back to reference Baumgart AM, Molinari MA, Silveira AC (2010) Prevalence of carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii in high complexity hospital. Braz J Infect Dis 14:433–436CrossRefPubMed Baumgart AM, Molinari MA, Silveira AC (2010) Prevalence of carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii in high complexity hospital. Braz J Infect Dis 14:433–436CrossRefPubMed
28.
go back to reference Scheffer MC, Gales AC, Barth AL, Carmo Filho JR, Dalla-Costa LM (2010) Carbapenem-resistant Pseudomonas aeruginosa: clonal spread in southern Brazil and in the state of Goiás. Braz J Infect Dis 14:508–509PubMed Scheffer MC, Gales AC, Barth AL, Carmo Filho JR, Dalla-Costa LM (2010) Carbapenem-resistant Pseudomonas aeruginosa: clonal spread in southern Brazil and in the state of Goiás. Braz J Infect Dis 14:508–509PubMed
29.
go back to reference Mutnick AH, Rhomberg PR, Sader HS, Jones RN (2004) Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999–2001). J Antimicrob Chemother 53:290–296CrossRefPubMed Mutnick AH, Rhomberg PR, Sader HS, Jones RN (2004) Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999–2001). J Antimicrob Chemother 53:290–296CrossRefPubMed
30.
go back to reference Harbarth S, Harris AD, Carmeli Y, Samore MH (2001) Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli. Clin Infect Dis 33:1462–1468CrossRefPubMed Harbarth S, Harris AD, Carmeli Y, Samore MH (2001) Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli. Clin Infect Dis 33:1462–1468CrossRefPubMed
Metadata
Title
Trends and correlation of antibacterial usage and bacterial resistance: time series analysis for antibacterial stewardship in a Chinese teaching hospital (2009–2013)
Authors
Y. M. Zou
Y. Ma
J. H. Liu
J. Shi
T. Fan
Y. Y. Shan
H. P. Yao
Y. L. Dong
Publication date
01-04-2015
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 4/2015
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-014-2293-6

Other articles of this Issue 4/2015

European Journal of Clinical Microbiology & Infectious Diseases 4/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.